Cipher Pharmaceuticals (CPH) to Release Earnings on Thursday

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) is scheduled to be releasing its earnings data after the market closes on Thursday, May 9th. Analysts expect Cipher Pharmaceuticals to post earnings of C$0.14 per share for the quarter.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last issued its quarterly earnings data on Thursday, March 14th. The company reported C$0.41 earnings per share for the quarter, beating analysts’ consensus estimates of C$0.15 by C$0.26. Cipher Pharmaceuticals had a net margin of 96.32% and a return on equity of 28.19%. The company had revenue of C$6.70 million for the quarter, compared to the consensus estimate of C$7.31 million.

Cipher Pharmaceuticals Stock Performance

Shares of CPH opened at C$9.24 on Wednesday. Cipher Pharmaceuticals has a one year low of C$3.11 and a one year high of C$9.98. The business has a fifty day moving average of C$8.36 and a 200 day moving average of C$6.76. The company has a debt-to-equity ratio of 0.44, a current ratio of 9.19 and a quick ratio of 2.67. The firm has a market capitalization of C$222.78 million, a P/E ratio of 8.40 and a beta of 1.04.

Analyst Upgrades and Downgrades

Separately, Citigroup boosted their price target on Cipher Pharmaceuticals from C$4.75 to C$8.00 and gave the company a “buy” rating in a report on Wednesday, February 14th.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.